

The USFDA approves the first long-acting injectable for HIV prevention

The Business Research Company's HIV Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030


LONDON, GREATER LONDON, UK, January 12, 2022 /EINPresswire.com/ -- Last few days of our annual market report sale! Buy now.

<https://www.thebusinessresearchcompany.com/global-market-reports>

On December 20, 2021, the USFDA approved GlaxoSmithKline ViiV Healthcare's Apretude, a cabotegravir extended-release injectable suspension – the first and only long-acting injectable product for HIV prevention. Apretude is an integrase strand transfer inhibitor (INSTI) and a long-acting injectable pre-exposure prophylaxis (PrEP) product to reduce the risk of sexually acquired HIV-1 in both men and women. The use of cabotegravir long-acting for PrEP as an injection every two months to prevent HIV can avoid daily medication.

The HIV drugs market will have stable growth in the next five years according to the estimates of [Global Market Model](#) of The Business Research Company. The global [HIV drugs market size](#) is expected to grow from \$30.5 billion in 2020 to \$40.3 billion in 2030 at a CAGR of 6.5%.

The growing prevalence of HIV and government initiatives for HIV treatment will drive the demand for HIV drugs. For instance, in 2021, there was the Health Resources and Services Administration's (HRSA) Bureau of Primary Health Care announced the funding of around \$83 million for up to 300 health centres for "Ending the HIV Epidemic – Primary Care HIV Prevention (PCHP) program". According to the World Health Organization (WHO) report 2020, HIV continues to be a global public health crisis, with an estimated 37.7 million people living with HIV worldwide and 1.7 million new cases annually. PrEP represents an effective tool to reduce new cases of HIV, which, when combined with appropriate HIV antiretroviral therapy, will help end the HIV epidemic.



TBRC's HIV drugs market report is segmented by type, application, administration, and geography:

- By Type- Nucleoside Reverse Transcriptase Inhibitors (NRTs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTs), Protease Inhibitors, Integrase Strand Transfer Inhibitors (INSTIs), Others
- By Application- Hospital Pharmacies, Retail Pharmacies, Others
- By Administration- Oral, Parenteral
- By Geography- North America, South America, Asia Pacific, Western Europe, Eastern Europe, Middle East, Africa

Research is sourced from TBRC's

reports(<https://www.thebusinessresearchcompany.com/report/hiv-drugs-market>), FDA(<https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention>), WHO(<https://www.who.int/news-room/fact-sheets/detail/hiv-aids>)

The forecasted revenue of the company is calculated based on the assumption that the company's market share will remain the same during the forecast period.

Here are some related reports:

Anti-Viral Drug Therapy Market - By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza), Anti-Viral Drug Therapy Market Size, Opportunities And Strategies - Global Anti-Viral Drug Therapy Market Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market>

About The Global Market Model:

The Global Market Model is the world's most comprehensive database of integrated market information available. The ten-year forecasts in the Global Market Model are updated in real-time to reflect the latest market realities, which is a huge advantage over static, report-based platforms.

Interested In Knowing More About [The Business Research Company?](#)

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. The Global Market Model is The Business Research Company's flagship product.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/560427090>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.